{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:33:08Z","timestamp":1791405188084,"version":"4.3.3"},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1523,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1600-0536.2011.01907.x","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T09:36:24Z","timestamp":1309512984000},"page":"227-230","source":"Crossref","is-referenced-by-count":17,"title":["Lack of effect of ustekinumab in treatment of allergic contact dermatitis"],"prefix":"10.1111","volume":"65","author":[{"given":"Nannie","family":"Bangsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkil","family":"Menn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrd2878","article-title":"Ustekinumab.","volume":"8","author":"Reich","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators. Efficacy and safety of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"PHOENIX 2 study investigators. Efficacy and safety of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Ustekinumab MS Investigators. Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, Ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4049\/jimmunol.167.1.156","article-title":"IL-12 augments CD8+ T cell development for contact hypersensitivity responses and circumvents anti-CD154 antibody-mediated.","volume":"167","author":"Gorbachev","year":"2001","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1084\/jem.20070509","article-title":"Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity.","volume":"205","author":"Martin","year":"2008","journal-title":"J Exp Med"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-9-19","article-title":"Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpot-analysis in contact dermatitis patients.","volume":"9","author":"Bordignon","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaci.2008.09.036","article-title":"IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis.","volume":"123","author":"Larsen","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.0901767","article-title":"IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes.","volume":"184","author":"Pennino","year":"2010","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.4049\/jimmunol.165.12.6783","article-title":"CD4+ Th1 and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity.","volume":"165","author":"Wang","year":"2000","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.4049\/jimmunol.159.5.2484","article-title":"Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile.","volume":"159","author":"Kitagaki","year":"1997","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0536.2011.01907.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1523-1747.1998.00239.x","article-title":"Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4.","volume":"111","author":"Webb","year":"1998","journal-title":"J Invest Dermatol"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0536.2011.01907.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0536.2011.01907.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T22:36:06Z","timestamp":1686177366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0536.2011.01907.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0536.2011.01907.x","relation":{},"ISSN":["0105-1873"],"issn-type":[{"value":"0105-1873","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}